Wei-Ting Hwang, Ph.D.

faculty photo
Professor of Biostatistics in Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania
Department: Biostatistics and Epidemiology
Graduate Group Affiliations

Contact information
Department of Biostatistics, Epidemiology and Informatics (DBEI)
Center for Clinical Epidemiology and Biostatistics (CCEB)
University of Pennsylvania Perelman School of Medicine
610 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
Office: 215-573-5946
Fax: 215-573-4865
B.S. (Mathematics)
National Tsing-Hua University, Taiwan, 1995.
Ph.D. (Biostatistics)
Johns Hopkins University, School of Hygiene and Public Health, 2001.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Biostatistics, survival data analysis, longitudinal studies, clinical trials, translational cancer research, biomarker discovery and validation, environmental health sciences, instrument development for psychosocial research

Selected Publications

Rogers AE, Hwang W-T, Scott LD, Aiken LH, Dinges DF: The working hours of hospital staff nurses and patient safety. Health Affairs 23(4): 202-212, Jul-Aug 2004 Notes: (1044 citations up to date).

Harris EE, Christensen VJ, Hwang W-T, Fox K, Solin LJ: Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. Journal of Clinical Oncology 23(1): 11-16, Jan 2005 Notes: (122 citations up to date).

Harris EE, Correa C, Hwang W-T, Liao J, Litt HI, Ferrari VA, Solin LJ: Late cardiac mortality and morbidity in early-stage breast cancer patients after breast conservation treatment. Journal of Clinical Oncology 24(25): 4100-4106, Sep 2006 Notes: (333 citations up to date).

Hwang W-T*, Adams SF*, Tahirovic E, Hagemann IS, Coukos G: Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecologic Oncology. *Equal Contribution. 124(2): 192-198, Feb 2012 Notes: **The second most cited paper on Gynecologic Oncology since 2012 (233 citations to date).

Scholler J, Brady TL, Binder-Scholl G, Hwang W-T, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH: Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine 4(132): 132ra53, May 2012 Notes: *Statistical lead (384 citations to date).

Baumann BC, Guzzo TJ, He J, Keefe SM, Tucker K, Bekelman JE, Hwang W-T, Vaughn DJ, Malkowicz SB, Christodouleas JP: A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy. International Journal of Radiation Oncology Biology Physics 85(1): 81-8, Jan 2013 Notes: *The first of a series of reports to identify who is most likely to benefit from adjuvant radiation for bladder cancer (36 citations to date).

Tebas P, Stein D, Binder-Scholl G, Mukherjee R, Brady T, Rebello T, Humeau L, Kalos M, Papasavvas E, Montaner LJ, Schullery D, Shaheen F, Brennan AL, Zheng Z, Cotte J, Slepushkin V, Veloso E, Mackley A, Hwang W-T, Aberra F, Zhan J, Boyer J, Collman RG, Bushman FD, Levine BL, June CH: Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. Blood 121(9): 1524-33, Feb 2013 Notes: *Statistical lead in this multidisciplinary team and report (81 citations to date).

Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang W-T, Levine BL, June CH: Gene editing of CCR5 in autologous CD4T cells of persons infected with HIV. New England Journal of Medicine 370(10): 901-10, Mar 2014 Notes: * Statistical lead for this first-in-man genome editing clinical trial (914 citations to date, 2015 Clinical Research Award).

Zhong Q, Peng HL, Zhao X, Zhang L*, Hwang W-T*: Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clinical Cancer Research. *Senior authors, 21(1): 211-20, Jan 2015 Notes: The study was conducted according to PRISMA and MOOSE guidelines (77 citations to date).

Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone M, Levine BL, Melenhorst JJ, June CH: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine 7(303): 303ra139, Sep 2015 Notes: *: Second/statistical lead author (513 citations to date).

Garfall AL*, Maus MV*, Hwang W-T**, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA: Chimeric antigen receptor T cells against CD19 for multiple myeloma. New England Journal of Medicine. *: Equal Contribution, 373(11): 1040-7, Sep 2015 Notes: ** Second/statistical author (276 citations to date).

Xu R, Mesaros C, Weng L, Snyder NW, Vachani A, Blair IA, Hwang W-T*: Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure. Biomarkers in Medicine 11(7): 547-556, Jul 2017 Notes: *Senior author. The work and funding for the first author (Xu) is supported by Penn Superfund Research Center Biostatistics Core.

Yu D, Hwang W-T: Optimal cutoffs for continuous biomarkers for survival data under competing risks. Communications in Statistics - Simulation and Computation Page: 1-16, Jan 2018 Notes: *: Senior author. doi:10.1080/03610918.2017.1410713.

Joseph A. Fraietta JA*, Lacey SF*, Orlando EJ*, Ambrose DE, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Frey NV, Hwang W-T**, Parakandi H, Gupta M, Huang A, Johnson B, Kulikovskaya I, Levine BL, Liu L, Lundh SM, Pequignot R, Siegel DL, Wang V, Wherry EJ, Xu J, Young RM, Brogdon JL, Bitter H3, Porter DL, June CJ, Melenhorst JJ : Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine 24(5): 563-571, May 2018 Notes: *: Equal contribution, **: Statistical lead.

back to top
Last updated: 08/01/2019
The Trustees of the University of Pennsylvania